The Effect of Vitamin D Levels on Inflammation in Patients With Chronic Renal Failure

Öz

It is suggested that a number of environmental and genetic factors trigger the formation of progressive kidney damage and complications. One of these factors is inflammation, it occurs as a result of a series of mechanisms included within a number of cytokines. Vitamin-D, IL-6, PCT and hs-CRP are also valuable biomarkers in terms of mortality in dialysis patients in this sense. Vitamin D deficiency is common in patients with chronic kidney disease (CKD)and is associated with inflammation. In recent years, some randomized controlled trials have revealed the effect of Vitamin D on inflammation in CKD patients, but the results are conflicting. The aim of our study is to investigate the relationship between Vitamin D, high-sensitivity C Reactive Protein (hs-CRP), procalcitonin and IL-6, and to evaluate the relation of Vitamin D levels with inflammation in PD patients, HD patients and controls. This study was carried on with 40 patients receiving on hemodialysis treatment, 40 patients receiving peritoneal treatment with renal failure disease and with a control group consisting of 40 healthy individuals. Vitamin D levels were measured by HPLC, PCT and IL-6 levels were measured by chemiluminescent method, hs-CRP is measured by nephelometric method. For Vitamin D, there was no differences between the groups. For PCT, there was a significant difference between all groups. For IL-6, while there was no difference between peritoneal and hemodialysis groups, a significant difference was determined between the peritoneal dialysis and control groups. For hs-CRP, there was a significant difference among all groups. While correlation was found between serum PCT levels with IL-6 and hs-CRP, no correlations were found between serum PCT with Vitamin D levels. Although a correlation was found between serum IL-6 levels and hs-CRP, no correlation was detected between serum IL-6 and Vitamin D levels. No correlations were detected between Vitamin D andPCT, IL-6 and hs-CRP.

Anahtar Kelimeler

• Hemodialysis
• High Sensitivity C-Reactive Protein
• Interleukin-6
• Peritoneal Dialysis
• Procalcitonin
• Vitamin D

References

1. Ali, F.N., Arguelles, L.M., Langman, C.B., and Price, H.E., (2009). Vitamin D Deficiency in Children with Chronic Kidney Disease: Uncovering an Epidemic. Pediatrics, 123:791–796.
2. Satirapoj, B., Limwannata, P., Chaiprasert, A., Supasyndh, O., and Choovichian, P., (2013). Vitamin D Insufficiency and Deficiency with Stages of Chronic Kidney Disease in an Asian Population. BMC Nephrol, 14:206.
3. Segerer, S., Nelson, P.J., and Schlondorff, D., (2000). Chemokines, Chemokine Receptors, and Renal Disease: from Basic Science to Pathophysiologic and Therapeutic Studies. J Am Soc Nephrol, 11:152-176.
4. Yao, Q., Lindholm, B., and Stenvinkel, P., (2004). Inflammation as a Cause of Malnutrition, Atherosclerotic Cardiovascular Disease, and Poor Outcome in Hemodialysis Patients. HemodialInt, 8:118–29.
5. Mizobuchi, M., Morrissey, J., Finch, J.L., Martin, D.R., Liapis, H., Akizawa, T., and Slatopolsky, E., (2007). Combination Therapy with an Angiotensin-Converting Enzyme Inhibitor and a Vitamin D Analog Suppresses the Progression of Renal Insufficiency in Uremic Rats. J Am Soc Nephrol, 18:1796–1806.
6. Panichi, V., Migliori, M., Taccola, D., Filippi, C., De Nisco, L., Giovannini, L., Palla, R., Tetta, C., and Camussi, G., (2001). Effects of 1.25(OH)2D3 in Experimental Mesangial Proliferative Nephritis in Rats. Kidney Int 60:87–95.
7. Makibayashi, K., Tatematsu, M., Hirata, M., Fukushima, N., Kusano, K., Ohashi, S., Abe, H., Kuze, K., Fukatsu, A., Kita, T., and Doi, T., (2001). A Vitamin D Analog Ameliorates Glomerular Injury on Rat Glomerulonephritis. Am J Pathol 158:1733–1741.
8. Park, J.W., Bae, E.H., Kim, I.J., et al., (2010). Renoprotective Effects of Paricalcitol on Gentamicin-Induced Kidney Injury in Rats. Am J Physiol Renal Physiol, 298:F301-F313.

9. Park, J.W., Bae, E.H., Kim, I.J., et al., (2010). Paricalcitol Attenuates Cyclosporine-Induced Kidney Injury in Rats. Kidney Int, 77:1076-1085.
10. Garcia, I.M., Altamirano, L., Mazzei, L., et al., (2012). Role of Mitochondria in Paricalcitol-Mediated Cytoprotection during Obstructive Nephropathy. Am J Physiol Renal Physiol, 302:F1595-F1605.
11. Guijarro, C. and Egido, J., (2001). Transcription Factor-Kappa B (NF-kappa B) and Renal Disease. Kidney Int, 59:415-424.
12. VinhquốcLu'o'ng, K. and Nguyễn, L.T., (2013). The Beneficial Role of Vitamin D in Obesity: Possible Genetic and Cell Signaling Mechanisms. Nutr J., 12–89.
13. Vitseva, O.I., Tanriverdi, K., Tchkonia, T.T., Kirkland, J.L., McDonnell, M.E., Apovian, C.M., Freedman, J., and Gokce, N., (2008). Inducible Toll-like Receptor and NF-kB Regulatory Pathway Expression in Human Adipose Tissue.Obesity (Silver Spring), 16:932–7.
14. Steinbach, G., Bölke, E., Grünert, A., Orth, K., and Störck, M., (2004). Procalcitonin in Patients with Acute and Chronic Renal Insufficiency. Wien Klin Wochenschr, 116(24):849-53.
15. Sitter, T., Schmidt, M., Schneider, S., and Schiffl, H., (2001). Differential Diagnosis of Bacterial Infection and Inflammatory Response in Kidney Diseases Using Procalcitonin. J of Nephrol, 15(3):297-301.
16. Koszegi, T., (2002). Immunoluminometric Detection of Human Procalcitonin. J BiochemBiophys Methods, 53(1):157-64.
17. Rao, M., Wong, C., Kanetsky, P., Girndt, M., Stenvinkel, P., Reilly, M., and Raj, D.S., (2007). Cytokine Gene Polymorphism and Progression of Renal and Cardiovascular Diseases, Kidney Int, 72:549–56.
18. Hasuike, Y., Nonoguchi, H., Ito, K., Naka, M., Kitamura, R., Nanami, M., Tokuyama, M., Kida, A., Otaki, Y., Kuragano, T., and Nakanishi, T., (2009). Interleukin-6 is a Predictor of Mortality in Stable Hemodialysis Patients. Am J Nephrol, 30:389-98.
19. Chiesa, C., Signore, F., Assuma, M., Buffone, E., Tramontozzi, P., Osborn, J., and Pacifico, L., (2001). Serial Measurements of C-Reactive Protein and Interleukin-6 in the Immediate Postnatal Period: Reference Intervals and Analysis of Maternal and Perinatal Confounders. Clin Chem, 47(6):1016-22.
20. Pearson, T.A., et. al., (2003). AHA/CDC Scientific Statement: Markers of Inflammation and Cardiovascular Disease-Application to Clinical and Public Health Practice. Circulation, 107:499-511.
21. Stenvinkel, P., Pecoits-Filho, R., and Lindholm, B., (2005). Gene Polymorphism Association Studies in Dialysis: The Nutrition-Inflammation Axis. Semin Dial, 18:322-30.
22. Stenvinkel, P., Chung, S.H., Heimbürger, O., and Lindholm, B., (2001). Malnutrition, Inflammation, and Atherosclerosis in Peritoneal Dialysis Patients. Perit Dial Int, 21(3):157–62.
23. Kumar, V., Yadav, A.K., Lal, A., et al., (2017). A Randomized Trial of Vitamin D Supplementation on Vascular Function in CKD. J AmSocNephrol, 28:3100–8.
24. Giakoumis, M., Tsioufis, C., Dimitriadis, K., et al., (2018). Effects of Oral Paricalcitol Therapy on Arterial Stiffness and Osteopontin in Hypertensive Patients with Chronic Kidney Disease and secondary hyperparathyroidism. Hellenic J Cardiol, https://doi.org/10.1016/j.hjc.2017.12.010.
25. Hewitt, N.A., O’Connor, A.A., O’Shaughnessy, D.V., and Elder, G.J., (2013). Effects of Cholecalciferol on Functional, Biochemical, Vascular, and Quality of Life Outcomes in Hemodialysis Patients. Clin J AmSocNephrol, 8:1143–9.
26. Mose, F.H., Vase, H., Larsen, T., et al., (2014). Cardiovascular Effects of Cholecalciferol Treatment in Dialysis Patients—A Randomized Controlled Trial. BMC Nephrol, 15:50.
27. Alborzi, P., Patel, N.A., Peterson, C., et al., (2008). Paricalcitol Reduces Albümin Uria and Inflammation in Chronic Kidney Disease: A Randomized Double-blind Pilot Trial. Hypertension, 52:249–55.
28. Dreyer, G., Tucker, A.T., Harwood, S.M., Pearse, R.M., Raftery, M.J., and Yaqoob, M.M., (2014). Ergocalciferol and Micro Circulatory Function in Chronic Kidney Disease and Concomitant Vitamin D Deficiency: an Exploratory, doubleblind, randomised controlled trial. PLoSOne, 9:e99461.
29. Levin, A., Tang, M., Perry, T., et al., (2017). Randomized Controlled Trial for the Effect of Vitamin D Supplementation on Vascular Stiffness in CKD. Clin J AmSocNephrol, 12:1447–60.
30. Lundwall, K., Jörneskog, G., Jacobson, S.H., and Spaak, J., (2015). Paricalcitol, Microvascular and Endothelial Function in Nondiabetic Chronic Kidney Disease: A Randomized Trial. Am J Nephrol, 42:265–73.
31. Tamadon, M.R., Soleimani, A., Keneshlou, F., et al., (2018). Clinical Trial on the Effects of Vitamin D Supplementation on Metabolic Profiles in Diabetic Hemodialysis. Horm Metab Res, 50:50–5.
32. Zoccali, C., Curatola, G., Panuccio, V., et al., (2014). Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial. Hypertension, 64:1005–11.
33. WHO Scientific Group on Prevention, Management of Osteoporosis, & World Health Organization. (2003). Prevention and management of osteoporosis: report of a WHO scientific group (No. 921). World Health Organization.
34. Holick, M.F., (2007). Vitamin D Deficiency. N Engl J Med, 357:266-281.
35. Lips, P., (2001). Vitamin D Deficiency and Secondary Hyperparathyroidism in the Elderly: Consequences for Bone Loss and Fractures and Therapeutic Implications. Endocr Rev, 22:477-501.
36. Kim, C.S. and Kim, S.W. (2014). Vitamin D and Chronic Kidney Disease. The Korean journal of internal medicine, 29(4):416.
37. Gonzalez, E., Sachdeva, A., Oliver, D., and Martin, K., (2004). Vitamin D Insufficiency and Deficiency in Chronic Kidney Disease. Am JNephrol, 24:503–10.
38. Saha, H., (1994). Calcium and Vitamin D Homeostasis in Patients with Heavy Proteinuria. Clin Nephrol, 41:290–6.
39. Portale, A.A., Booth, B.E., Halloran, B.P., and Morris, R.C., (1984). Effect of Dietary Phosphorus on Circulating Concentrations of 1,25-dihydroxy Vitamin D and Immunoreactive Parathyroid Hormone in Children with Moderate Renal Insufficiency. J Clin Invest, 73:1580–9.
40. Hsu, C.H., Vanholder, R., Patel, S., et al., (1991). Subfractions in Uremic Plasma Ultrafiltrate Inhibit Calcitriol Metabolism. Kidney Int, 40:868–973.
41. Husain, T.M. and Kim, D.H., (2002). C-Reactive Protein and Erytrocyte Sedimentation Rate in Orthopaedics. The Ues Penn Orth J, 15:13–6.
42. Honda, H., et. al., (2006). Serum Albumin, C-Reactive Protein, Interleukin 6, and Fetuina as Predictors of Malnutrition, Cardiovascular Disease, and Mortality in Patients with ESRD. Am J Kidney Dis, 47(1):139-48.
43. Zhang, W., He, J., Zhang, F., Huang, C., Wu, Y., Han, Y., et. al., (2013). Prognostic Role of C-Reactive Protein and Interleukin-6 in Dialysis Patients: A Systematic Review and Meta-Analysis.J Nephrol, 26(2):243-53.
44. Atli, T., Gullu, S., Uysal, A.R., and Erdogan, G., (2005). The Prevalence of Vitamin D Deficiency and Effects of Ultraviolet Light on Vitamin D Levels in Elderly Turkish Population. Arch GerontolGeriatr, 40:53-60.
45. Alagöl, F., Shihadeh, Y., Boztepe, H., Tanakol, R., Yarman, S., Azizlerli, H., and Sandalci, O., (2000). Sunlight Exposure and Vitamin D Deficiency in Turkish Women. J Endocrinol Invest, 23:173-177.
46. Guzel, R., Kozanoglu, E., Guler-Uysal, F., Soyupak, S., and Sarpel, T., (2001). Vitamin D Status and Bone Mineral Density of Veiled and Unveiled Turkish Women. J Womens Health Gend Based Med, 10:765-770.
47. Erkal, M.Z., Wilde, J., Bilgin, Y., Akinci, A., Demir, E., Bödeker, R.H., Mann, M., Bretzel, R.G., Stracke, H., and Holick, M.F., (2006). High Prevalence of Vitamin D Deficiency, Secondary Hyperparathyroidism and Generalized Bone Pain in Turkish Immigrants in Germany: Identification of Risk Factors. Osteoporos Int, 17:1133-1140.
48. Hekimsoy, Z., Dinc, G., Kafesciler, S., Onur, E., Guvenc, Y., Pala, T., Guclu, F., and Ozmen, B., (2010). Vitamin D Status among Adults in the Aegean Region of Turkey. BMC Public Health, 10: 782.
49. Uçar, F., Taşlıpınar, M.Y., Soydaş, A.Ö. ve Özcan, N., (2012). Ankara Etlik İhtisas Eğitim Araştırma Hastanesi’ne Başvuran Hastalarda 25-OH Vitamin D Levels. Eur J Basic Med Sci, 2:12-5.
50. Binnetoğlu, E.D., (2009). Association Between Vitamin D and Proteinuria in Chronic Kidney Disease, Faculty of Medicine, Department of Internal Diseases. Specialization in Medicine Thesis, Kocaeli: Kocaeli University.
51. Opatrna, S., et. al., (2005). Procalcitonin Levels in Peritoneal Dialysis Patients. Periton Dialysis Int, 25(5):470-2.1
52. Herget, R., et. al., (2005). Modulation and Source of Procalcitonin in Reduced Renal Function and Renal Replacement Therapy. Scand J Immunol, 61(2):180-6.
53. Visvardis, G., et. al., (2005). Relevance of Procalcitonin Levels in Comparison to Other Markers of Inflammation in Hemodialysis Patients. Ren Fail, 27(4):429-34.
54. Mori, K.I., Noguchi, M., Sumino, Y., Sato, F., and Mimata, H., (2012). Use of Procalcitonin in Patients on Chronic Hemodialysis: Procalcitonin is not Related with Increased Serum Calcitonin.ISRN Urology, 2012.
55. Level, C., Chauveau, P., Delmas, Y., Lasseur, C., Pellé, G., Peuchant, E., et. al., (2001). Procalcitonin: A New Marker of Inflammation in Hemodialysis Patients?. Nephrol Dial Transpl, 16(5):980-6.